MXCT
MaxCyte, Inc.1.4700
-0.0200-1.34%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q3 '25
Key Stats
Market Cap
156.81MP/E (TTM)
-Basic EPS (TTM)
-0.43Dividend Yield
0%Recent Filings
10-Q
8-K
Q3 revenue drops 16%
MaxCyte reported Q3 2025 revenue of $6.8M, down 16% from $8.2M last year, with core revenue falling 21% to $6.4M yet SPL program revenue surging to $0.4M. Restructuring slashed costs, trimming op ex to $19.4M; cash stands at $158M. Guidance holds: core revenue flat to -10%, SPL ~$5M, year-end cash $152M-$155M. Losses widened slightly.
8-K
8-K
8-K
CCO Soleymannezhad departs MaxCyte
MaxCyte's Chief Commercial Officer Ali Soleymannezhad departed on August 11, 2025, triggering a nine-month severance payout of his base salary and COBRA contributions, contingent on signing a release. This exit removes key commercial leadership amid the biotech's push for cell therapy partnerships. No interim replacement disclosed. The change risks short-term sales momentum.
BLFS
BioLife Solutions, Inc.
24.61-0.04
CTKB
Cytek Biosciences, Inc.
4.70+0.06
CTSO
Cytosorbents Corporation
0.64+0.01
IART
Integra LifeSciences Holdings C
13.00-0.47
LAB
Standard BioTools Inc.
1.49-0.02
MASS
908 Devices Inc.
5.78-0.13
MDNC
MEDINOTEC INC
5.00+0.00
MDT
Medtronic plc.
97.72-0.85
PLSE
Pulse Biosciences, Inc
14.23+0.10
RCEL
Avita Medical, Inc.
3.33-0.07